WO2008019144A2 - Threapeutic methods for treating vascular eye disorders with dll4 antagonists - Google Patents
Threapeutic methods for treating vascular eye disorders with dll4 antagonists Download PDFInfo
- Publication number
- WO2008019144A2 WO2008019144A2 PCT/US2007/017546 US2007017546W WO2008019144A2 WO 2008019144 A2 WO2008019144 A2 WO 2008019144A2 US 2007017546 W US2007017546 W US 2007017546W WO 2008019144 A2 WO2008019144 A2 WO 2008019144A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dii4
- antibody
- ischemic
- retinal
- retinopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MEP-31/09A ME00591A (en) | 2006-08-07 | 2007-08-07 | Use of dii4 antagonists in ishemic injury or vascular insufficiency |
RS20130078A RS52685B (en) | 2006-08-07 | 2007-08-07 | Use of dii4 antagonists in ischemic injury or vascular insufficiency |
KR1020097004668A KR101497355B1 (en) | 2006-08-07 | 2007-08-07 | Dll4 antagonists and pharmaceutical compositions comprising them for treating an ischemic injury or vascular insufficiency |
CA2660235A CA2660235C (en) | 2006-08-07 | 2007-08-07 | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
PL07811137T PL2054082T3 (en) | 2006-08-07 | 2007-08-07 | Use of Dll4 antagonists in ischemic injury or vascular insufficiency |
JP2009523820A JP5529536B2 (en) | 2006-08-07 | 2007-08-07 | Use of Dll4 antagonists in the treatment of ischemic injury or vascular failure |
BRPI0716424A BRPI0716424B8 (en) | 2006-08-07 | 2007-08-07 | use of delta-like ligand antagonist 4 (dll4) |
DK07811137.4T DK2054082T3 (en) | 2006-08-07 | 2007-08-07 | Use of D114 antagonists to treat ischemic injury or vascular insufficiency |
ES07811137T ES2398253T3 (en) | 2006-08-07 | 2007-08-07 | Use of DII4 antagonists in ischemic injury or vascular insufficiency |
CN200780029497.8A CN101500605B (en) | 2006-08-07 | 2007-08-07 | Use of Dll4 antagonists in treating local ischemic injury |
MX2009000674A MX2009000674A (en) | 2006-08-07 | 2007-08-07 | Threapeutic methods for treating vascular eye disorders with dll4 antagonists. |
NZ574794A NZ574794A (en) | 2006-08-07 | 2007-08-07 | Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury |
SI200731170T SI2054082T1 (en) | 2006-08-07 | 2007-08-07 | Use of Dll4 antagonists in ischemic injury or vascular insufficiency |
EP07811137A EP2054082B1 (en) | 2006-08-07 | 2007-08-07 | Use of Dll4 antagonists in ischemic injury or vascular insufficiency |
AU2007281916A AU2007281916B2 (en) | 2006-08-07 | 2007-08-07 | methods for treating Ischemic Injury or Vascular Insuffciency |
ZA2009/00337A ZA200900337B (en) | 2006-08-07 | 2009-01-15 | Use of dii4 antagonists in treating ischemic injury or vascular insuffiency |
IL196612A IL196612A (en) | 2006-08-07 | 2009-01-20 | Dll4 antagonist for reduction of blood vessel loss or promotion of angiogenesis |
TN2009000036A TN2009000036A1 (en) | 2006-08-07 | 2009-02-03 | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
NO20090984A NO341857B1 (en) | 2006-08-07 | 2009-03-04 | Use of a delta-like ligand 4 (D114) antagonist for the manufacture of a medicament for preventing or reducing blood vessel loss or promoting productive angiogenesis in a subject having ischemic injury or vascular insufficiency. |
HK10101051.2A HK1137339A1 (en) | 2006-08-07 | 2010-01-29 | Use of dll4 antagonists in treating local ischemic injury dll4 |
HRP20130271TT HRP20130271T1 (en) | 2006-08-07 | 2013-03-25 | Use of dii4 antagonists in ischemic injury or vascular insufficiency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83600306P | 2006-08-07 | 2006-08-07 | |
US60/836,003 | 2006-08-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008019144A2 true WO2008019144A2 (en) | 2008-02-14 |
WO2008019144A3 WO2008019144A3 (en) | 2008-03-27 |
Family
ID=38904599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/017546 WO2008019144A2 (en) | 2006-08-07 | 2007-08-07 | Threapeutic methods for treating vascular eye disorders with dll4 antagonists |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080181893A1 (en) |
EP (1) | EP2054082B1 (en) |
JP (1) | JP5529536B2 (en) |
KR (1) | KR101497355B1 (en) |
CN (1) | CN101500605B (en) |
AU (1) | AU2007281916B2 (en) |
BR (1) | BRPI0716424B8 (en) |
CA (1) | CA2660235C (en) |
CO (1) | CO6150190A2 (en) |
CR (1) | CR10627A (en) |
DK (1) | DK2054082T3 (en) |
ES (1) | ES2398253T3 (en) |
GT (1) | GT200900029A (en) |
HK (1) | HK1137339A1 (en) |
HR (1) | HRP20130271T1 (en) |
IL (1) | IL196612A (en) |
MA (1) | MA30667B1 (en) |
ME (1) | ME00591A (en) |
MX (1) | MX2009000674A (en) |
MY (1) | MY150092A (en) |
NO (1) | NO341857B1 (en) |
NZ (1) | NZ574794A (en) |
PL (1) | PL2054082T3 (en) |
PT (1) | PT2054082E (en) |
RS (1) | RS52685B (en) |
RU (1) | RU2429876C2 (en) |
SG (1) | SG174033A1 (en) |
SI (1) | SI2054082T1 (en) |
SV (1) | SV2009003161A (en) |
TN (1) | TN2009000036A1 (en) |
UA (1) | UA95304C2 (en) |
WO (1) | WO2008019144A2 (en) |
ZA (1) | ZA200900337B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2125013A1 (en) * | 2007-01-26 | 2009-12-02 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
WO2010032060A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies directed to dll4 and uses thereof |
US20100303812A1 (en) * | 2007-05-15 | 2010-12-02 | Smart Targeting Limited | Neutralizing monoclonal antibody against human dll4 |
WO2011039370A1 (en) * | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
WO2011094465A1 (en) | 2010-01-29 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating autoimmune diseases with dll4 antagonists |
EP2542582A2 (en) * | 2010-03-02 | 2013-01-09 | Abbvie Inc. | Therapeutic dll4 binding proteins |
RU2530583C2 (en) * | 2008-09-10 | 2014-10-10 | Дженентек, Инк. | Methods of inhibiting ocular angiogenesis |
US9132190B2 (en) | 2009-08-29 | 2015-09-15 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
EP2906295A4 (en) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | Methods of treating ocular diseases |
US9403904B2 (en) | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US10730940B2 (en) | 2011-09-23 | 2020-08-04 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2066694T1 (en) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
WO2011008641A1 (en) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Methids of modulating angiogenesis and treatment of angiogenesis-related diseases |
US8883145B2 (en) * | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
JP6371294B2 (en) | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods and monitoring of treatment with DLL4 antagonists |
US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2018094267A1 (en) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Novel methods to enhance microvascular engraftment of bioengineered and primary tissues |
WO2023063842A1 (en) | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Nucleotide sequence encoding a fusion protein |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060030529A1 (en) | 1999-06-08 | 2006-02-09 | Wiegand Stanley J | Use of VEGF inhibitors for treatment of eye disorders |
US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
WO2007028110A2 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
WO2007143689A2 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
-
2007
- 2007-08-07 ME MEP-31/09A patent/ME00591A/en unknown
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/en active Application Filing
- 2007-08-07 EP EP07811137A patent/EP2054082B1/en active Active
- 2007-08-07 PL PL07811137T patent/PL2054082T3/en unknown
- 2007-08-07 ES ES07811137T patent/ES2398253T3/en active Active
- 2007-08-07 SI SI200731170T patent/SI2054082T1/en unknown
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/en active Active
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/en active
- 2007-08-07 RS RS20130078A patent/RS52685B/en unknown
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/en active IP Right Grant
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/en active Active
- 2007-08-07 UA UAA200902033A patent/UA95304C2/en unknown
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/en active IP Right Grant
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/en active IP Right Grant
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/en active
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 PT PT78111374T patent/PT2054082E/en unknown
- 2007-08-07 CA CA2660235A patent/CA2660235C/en active Active
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/en unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/en unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/en unknown
- 2009-02-20 CR CR10627A patent/CR10627A/en unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/en unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/en unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/en unknown
-
2010
- 2010-01-29 HK HK10101051.2A patent/HK1137339A1/en unknown
-
2013
- 2013-03-25 HR HRP20130271TT patent/HRP20130271T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060030529A1 (en) | 1999-06-08 | 2006-02-09 | Wiegand Stanley J | Use of VEGF inhibitors for treatment of eye disorders |
US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
WO2007028110A2 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
WO2007143689A2 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2125013A1 (en) * | 2007-01-26 | 2009-12-02 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
EP2125013A4 (en) * | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Dll4 signaling inhibitors and uses thereof |
US20100303812A1 (en) * | 2007-05-15 | 2010-12-02 | Smart Targeting Limited | Neutralizing monoclonal antibody against human dll4 |
US8404233B2 (en) * | 2007-05-15 | 2013-03-26 | Smart Targeting Limited | Neutralizing monoclonal antibody against human DLL4 |
RU2530583C2 (en) * | 2008-09-10 | 2014-10-10 | Дженентек, Инк. | Methods of inhibiting ocular angiogenesis |
JP2012502650A (en) * | 2008-09-19 | 2012-02-02 | メディミューン,エルエルシー | Antibodies against DLL4 and uses thereof |
US9206255B2 (en) * | 2008-09-19 | 2015-12-08 | Medimmune, Llc | Nucleic acid molecule encoding target antibodies directed to DLL4 |
US8192738B2 (en) | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
EP2927244A1 (en) * | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
AU2009294415B2 (en) * | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
US8663636B2 (en) | 2008-09-19 | 2014-03-04 | Medimmune, Llc | Method of treating a malignant tumor by administering antibodies directed to DLL4 |
US20140206853A1 (en) * | 2008-09-19 | 2014-07-24 | Medimmune, Llc | Targeted binding agents directed to dll4 and uses thereof |
WO2010032060A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies directed to dll4 and uses thereof |
US9403904B2 (en) | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
US9469688B2 (en) | 2009-08-29 | 2016-10-18 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
US9132190B2 (en) | 2009-08-29 | 2015-09-15 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
CN102639566A (en) * | 2009-10-02 | 2012-08-15 | 贝林格尔.英格海姆国际有限公司 | Bispecific binding molecules for anti-angiogenesis therapy |
WO2011039370A1 (en) * | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
US8889133B2 (en) | 2010-01-29 | 2014-11-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes with Dll4 antagonists |
WO2011094467A3 (en) * | 2010-01-29 | 2011-12-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes with dll4 antagonists |
US8765125B2 (en) | 2010-01-29 | 2014-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating autoimmune diseases with Dll4 antagonists |
WO2011094465A1 (en) | 2010-01-29 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating autoimmune diseases with dll4 antagonists |
WO2011094467A2 (en) | 2010-01-29 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes with dll4 antagonists |
EP3072904A1 (en) * | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Therapeutic dll4 binding proteins |
EP3680253A3 (en) * | 2010-03-02 | 2020-09-30 | AbbVie Inc. | Therapeutic dll4 binding proteins |
TWI511742B (en) * | 2010-03-02 | 2015-12-11 | 艾伯維有限公司 | Therapeutic dll4 binding proteins |
EP2542582A2 (en) * | 2010-03-02 | 2013-01-09 | Abbvie Inc. | Therapeutic dll4 binding proteins |
US9115195B2 (en) | 2010-03-02 | 2015-08-25 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
US9469689B2 (en) | 2010-03-02 | 2016-10-18 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
EP2542582A4 (en) * | 2010-03-02 | 2013-12-04 | Abbvie Inc | Therapeutic dll4 binding proteins |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US10414828B2 (en) | 2011-04-01 | 2019-09-17 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and Ang2 |
US11161916B2 (en) | 2011-04-01 | 2021-11-02 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and Ang2 |
US10730940B2 (en) | 2011-09-23 | 2020-08-04 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US11512128B2 (en) | 2011-09-23 | 2022-11-29 | Mereo Biopharma 5, Inc. | VEGF/DLL4 binding agents and uses thereof |
EP2906295A4 (en) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | Methods of treating ocular diseases |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2054082B1 (en) | Use of Dll4 antagonists in ischemic injury or vascular insufficiency | |
US20200231703A1 (en) | Treatment of ocular disease | |
KR101244113B1 (en) | Connective tissue growth factor antibodies | |
NZ514434A (en) | Modulation of vascular permeability by means of TIE2 receptor activators | |
KR102096509B1 (en) | Anti-Tspan12 antibody or antigen-binding fragment thereof, and use thereof | |
KR20120099862A (en) | Pharmaceutical composition comprising neonatal fc receptor binding inhibitor | |
US20160331807A1 (en) | Therapeutic use of vegfr-3 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 0900863 Country of ref document: KE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780029497.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07811137 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2009000028 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/000674 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12009500184 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007811137 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009010129 Country of ref document: EG |
|
ENP | Entry into the national phase |
Ref document number: 2660235 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009523820 Country of ref document: JP Ref document number: 2007281916 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 574794 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2009-010627 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2007281916 Country of ref document: AU Date of ref document: 20070807 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09022898 Country of ref document: CO Ref document number: 1020097004668 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1304/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009107921 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2013/0078 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: PI0716424 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090209 |